Philip R. Mayeux, Ph.D.

SPaT MayeuxProfessor and Vice Chair, Director of Education
Program Director of SPaT T32 Training Grant
Program Director, SURF Program
Phone:  (501) 686-8895
Fax: (501) 686-5521


Ph.D. – Tulane University, 1987

Research Interests

Acute renal failure is a frequent and serious complication of septic shock in humans. My research is focused on the study of animal models of renal injury associated with sepsis. Studies are directed toward understanding the biochemical and physiological mechanisms triggered by sepsis that lead to cellular injury and organ failure. Our primary interests are in understanding the development of oxidant stress caused by reactive oxygen and nitrogen species as mediators of renal injury and evaluating new therapeutic approaches to prevent renal injury or accelerate recovery.

Meet Dr. Mayeux’s Research Team

Recent Research Support

Current Research
R01 GM106419  NIH/NIGMS  (CoPI)  (02/01/14 – 01/31/18)
“Mitochondrial injury and repair in sepsis-induced acute kidney injury”

T32 GM106999 (Program Director)  (07/01/13 – 06/30/18)
“Systems Pharmacology and Toxicology Training Program”

15GRNT2508025  American Heart Association  (PI)   (07/01/15 – 06/30/17)
“Preclinical studies in a rat pup model of infant sepsis-induced cardiorenal syndrome”

F31 DK104533  NIH/NIDDK  (Sponsor)   (01/01/15 – 12/13/17)
“Targeting renal perfusion and mitochondrial oxidants in a model of infant sepsis”

Completed Research
NIH/NIDDK R01 DK075991 (07/31/08 – 05/31/14)
“Mechanistic targets of intervention in sepsis-induced renal injury”


Sims CR, Nguyen TC, Mayeux PR. Could biomarkers direct therapy for the septic patient? J. Pharmacol. Exp. Ther. 357:228-239, 2016 (PMID: 26857961).

Smith JA, Mayeux PR, Schnellmann RG. Delayed MEK/ERK inhibition by trametinib attenuates systemic inflammatory responses and multi-organ injury in murine sepsis. Crit. Care Med. 44:e711-20, 2016 (PMID: 27031380).

Li Y, Hadden C, Cooper A, Ahmed A, Wu H, Lupashin V, Mayeux PR, Kilic F. Sepsis-induced elevation in plasma serotonin facilitates endothelial hyperpermeability. Sci. Rep. 6:22747, 2016 (PMID: 26956613).

Ince C, Mayeux PR, Nguyen T, Gomez H, Kellum JA, Ospina-Tascon GA, Hernandez G, Murray P, De Backer D. The endothelium in sepsis. Shock. 45:259-270, 2016 (PMID: 26871664).

Wang Z, Sims CR, Patil NK, Gokden N, Mayeux PR. Pharmacological targeting of sphingosine-1-phosphate receptor 1 improves the renal microcirculation during sepsis in the mouse. J Pharmacol. Exp. Ther. 352:61-66, 2015 (PMID: 25355645).

Sims CR, MacMillan-Crow LA, Mayeux PR. Targeting mitochondrial oxidants may facilitate recovery of renal function during infant sepsis. Clin. Pharmacol. Ther. 96:662-664, 2014 (PMID: 52148376).

Patil NK, Parajuli N, MacMillan-Crow LA, Mayeux PR. Inactivation of renal mitochondrial respiratory complexes and manganese superoxide dismutase during sepsis: mitochondrial-targeted antioxidant mitigates injury. Am. J. Physiol. Renal Physiol. 306:F734-F743, 2014 (PMID: 24500690).

Holthoff JH, Wang Z, Patil NK, Gokden N, Mayeux PR. Rolipram improves renal perfusion and function during sepsis in the mouse. J. Pharmacol. Exp. Ther. 347:357-364, 2013 (PMID: 24018639).

Holthoff JH, Wang Z, Seely KA, Gokden N, Mayeux PR. Resveratrol improves renal microcirculation, protects the tubular epithelium, and prolongs survival in a mouse model of sepsis-induced acute kidney injury. Kidney Int. 81:370-378, 2012 (PMID: 21975863).

Mayeux PR, MacMillan-Crow LA. Pharmacological targets in the renal peritubular microenvironment: implications for therapy for sepsis-induced acute kidney injury. Pharmacol. Ther. 134:139-155, 2012 (PMID: 22274552).

View Dr. Mayeux’s Publication List